KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Change in Account Payables (2016 - 2025)

Acadia Pharmaceuticals has reported Change in Account Payables over the past 16 years, most recently at -$10.8 million for Q4 2025.

  • Quarterly results put Change in Account Payables at -$10.8 million for Q4 2025, down 275.35% from a year ago — trailing twelve months through Dec 2025 was -$5.3 million (down 291.49% YoY), and the annual figure for FY2025 was -$5.3 million, down 291.49%.
  • Change in Account Payables for Q4 2025 was -$10.8 million at Acadia Pharmaceuticals, down from $1.6 million in the prior quarter.
  • Over the last five years, Change in Account Payables for ACAD hit a ceiling of $5.2 million in Q4 2023 and a floor of -$10.8 million in Q4 2025.
  • Median Change in Account Payables over the past 5 years was $818000.0 (2022), compared with a mean of $120500.0.
  • Biggest five-year swings in Change in Account Payables: soared 993.26% in 2022 and later tumbled 275.35% in 2025.
  • Acadia Pharmaceuticals' Change in Account Payables stood at -$846000.0 in 2021, then skyrocketed by 423.64% to $2.7 million in 2022, then surged by 91.12% to $5.2 million in 2023, then plummeted by 155.21% to -$2.9 million in 2024, then tumbled by 275.35% to -$10.8 million in 2025.
  • The last three reported values for Change in Account Payables were -$10.8 million (Q4 2025), $1.6 million (Q3 2025), and $2.0 million (Q2 2025) per Business Quant data.